New study aims to unlock secrets of lung cancer drug through blood tests
NCT ID NCT07468656
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine release syndrome. The goal is to improve treatment for future patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?
- Can a remote approach bring clinical trials to lung cancer patients?
- Which palliative care approach boosts quality of life in advanced lung cancer?